| Literature DB >> 32398876 |
Fatima Amanat1,2, Daniel Stadlbauer1, Shirin Strohmeier1,3, Thi H O Nguyen4, Veronika Chromikova1, Meagan McMahon1, Kaijun Jiang1, Guha Asthagiri Arunkumar1,2, Denise Jurczyszak1,2, Jose Polanco1,5, Maria Bermudez-Gonzalez1, Giulio Kleiner1, Teresa Aydillo1,6, Lisa Miorin1,6, Daniel S Fierer7, Luz Amarilis Lugo7, Erna Milunka Kojic7, Jonathan Stoever8, Sean T H Liu1,7,9,10, Charlotte Cunningham-Rundles11,12, Philip L Felgner13, Thomas Moran1, Adolfo García-Sastre1,6,7,14, Daniel Caplivski15, Allen C Cheng16, Katherine Kedzierska4, Olli Vapalahti17,18,19, Jussi M Hepojoki17,20, Viviana Simon1,6,7, Florian Krammer21.
Abstract
Here, we describe a serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters. This assay does not require the handling of infectious virus, can be adjusted to detect different antibody types in serum and plasma and is amenable to scaling. Serological assays are of critical importance to help define previous exposure to SARS-CoV-2 in populations, identify highly reactive human donors for convalescent plasma therapy and investigate correlates of protection.Entities:
Mesh：
Year: 2020 PMID： 32398876 DOI： 10.1038/s41591-020-0913-5
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440